Join Growin Stock Community!

Biomarin pharmaceutical inc.BMRN.US Overview

US StockHealthcare
(No presentation for BMRN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BMRN AI Insights

BMRN Overall Performance

BMRN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BMRN Recent Performance

-2.27%

Biomarin pharmaceutical inc.

0.05%

Avg of Sector

-0.31%

S&P500

BMRN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BMRN Key Information

BMRN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BMRN Profile

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Price of BMRN

BMRN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BMRN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
22.95
Forward PE
14.41
PS Ratio (TTM)
3.68
PB Ratio
1.94
Price-to-FCF
15.99
METRIC
VALUE
vs. INDUSTRY
Gross Margin
77.73%
Net Margin
10.83%
Revenue Growth (YoY)
12.87%
Profit Growth (YoY)
10.12%
3-Year Revenue Growth
17.61%
3-Year Profit Growth
13.44%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.82
PE Ratio (TTM)
22.95
Forward PE
14.41
PS Ratio (TTM)
3.68
PB Ratio
1.94
Price-to-FCF
15.99
Gross Margin
77.73%
Net Margin
10.83%
Revenue Growth (YoY)
12.87%
Profit Growth (YoY)
10.12%
3-Year Revenue Growth
17.61%
3-Year Profit Growth
13.44%

  • When is BMRN's latest earnings report released?

    The most recent financial report for Biomarin pharmaceutical inc. (BMRN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BMRN's short-term business performance and financial health. For the latest updates on BMRN's earnings releases, visit this page regularly.

  • Where does BMRN fall in the P/E River chart?

    According to historical valuation range analysis, Biomarin pharmaceutical inc. (BMRN)'s current price-to-earnings (P/E) ratio is 33.69, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of BMRN?

    According to the latest financial report, Biomarin pharmaceutical inc. (BMRN) reported an Operating Profit of -44.61M with an Operating Margin of -5.1% this period, representing a decline of 127.64% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BMRN's revenue growth?

    In the latest financial report, Biomarin pharmaceutical inc. (BMRN) announced revenue of 874.57M, with a Year-Over-Year growth rate of 17.03%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does BMRN have?

    At the end of the period, Biomarin pharmaceutical inc. (BMRN) held Total Cash and Cash Equivalents of 1.31B, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BMRN go with three margins increasing?

    In the latest report, Biomarin pharmaceutical inc. (BMRN) did not achieve the “three margins increasing” benchmark, with a gross margin of 68.5%%, operating margin of -5.1%%, and net margin of -5.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BMRN's profit trajectory and future growth potential.

  • Is BMRN's EPS continuing to grow?

    According to the past four quarterly reports, Biomarin pharmaceutical inc. (BMRN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BMRN?

    Biomarin pharmaceutical inc. (BMRN)'s Free Cash Flow (FCF) for the period is 58.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 64.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BMRN?

    The latest valuation data shows Biomarin pharmaceutical inc. (BMRN) has a Price-To-Earnings (PE) ratio of 33.69 and a Price/Earnings-To-Growth (PEG) ratio of -1.22. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.